Optimal use of SGLT2i and GLP-1 RA in the management of type 2 diabetes mellitus

AIM-T2DM Real World Study →


AIM-T2DM version 1.0


Primary Care

Identification Rate

81.8 patients / physician / year (Whole Database screening)


Whole Database


Canada (Class I MDSW), United States (CDSS)

This page was last updated 14 November 2023


Optimal use of SGLT2 inhibition and GLP-1 RA in the management of type 2 diabetes mellitus


AIM-T2DM classifies individual patients as eligible for medical management with a sodium-glucose cotransporter 2 (“SGLT2”) inhibitor or glucagon-like peptide-1 receptor agonist (“GLP-1 RA”) according to Chapter 13 of the 2020 Diabetes Canada guidelines ↗︎. Its input parameters are extracted from electronic health records by the Operations team of Ensho Health using the Apollo aEDC system and include:


AIM-T2DM is available as a monitoring service for whole electronic medical record databases ("Whole Database"). Whole Database analyses include all patients for which an office encounter was billed in the previous 90 days and recur every 90 days until terminated through Compass.

Requests for analyses can be made to eligible Data Labs by general practitioners:

All requests placed between the hours of 8:00am and 8:00pm Monday through Friday are reviewed by a member of the Clinical Operations team within 48 hours. Requests for Single Record analyses are fulfilled within 72 hours. Requests for Whole Database screens are fulfilled within 10 business days.


Comprehensive reports ↗︎ are prepared and distributed for each patient eligible for SGLT2 inhibition or medical management with a GLP-1 RA. Each report includes:

Reports are made available online in HTML and PDF formats through Compass. Requesting physicians and office staff are notified of new results by email.


Contact sales@ensho.ai for pricing

Intended Use

AIM-T2DM is intended for use as a decision support tool to aid qualified healthcare professionals in identifying individuals in which Chapter 13 of the 2020 Diabetes Canada guidelines recommend medical management with an SGLT2 inhibitor or GLP-1 RA. It is not diagnostic and does not replace the independent judgment of the treating physician. Any medical diagnosis and all decisions related to patient care and treatment choices should be based on the independent judgment of the treating physician and should take into account all information related to the patient, including without limitation, the patient and family history, direct physical examination and diagnostic tests.


AIM-T2DM is a process for converting input parameters to a likelihood estimate. It is deployed at the Toronto, Canada Data Lab of Ensho Health through the AIM-T2DM Module ("CDL Module"). The CDL Module is comprised of the AIM-T2DM Algorithm ("Algorithm") which encodes it in software and a graphical user interface called the AIM-T2DM Controller ("Controller"). The CDL Module is deployed exclusively at the Toronto Data Lab of Ensho Health where it is applied to the data of requesting physicians as a service. The CDL Module was developed to the ISO 13485:2016 standard for medical devices in compliance with Ensho’s Quality Management System.

United States

The AIM-T2DM CDL Module is classified as Clinical Decision Support Software according to Food and Drug Administration guidance FDA-2017-D-6569 ↗︎ on the interpretation of Section 3060(a) of the 21st Century Cures Act (Cures Act) since its input parameters are clinical characteristics recorded in patient charts at a single point in time (criterion 1-2) and it provides established guideline recommendations to health care professionals whose basis are clearly communicated (criterion 3-4).


The AIM-T2DM CDL Module is Clinical Decision Support Software in Canada.

Rest of World

The AIM-T2DM CDL Module is not yet available in Australia, European Union member states or Israel.